Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01129362 · ClinicalTrials.gov registry record
Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines
A clinical trial, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- 1,195
- Enrollment target
NCT01129362: Completed study, sponsored by Sanofi Pasteur, a Sanofi Company.
NCT01129362 is a clinical trial that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 1,195 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01129362 has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- 1,195 participants
- Enrollment target
Study Summary
The purpose of this cohort study is to determine vaccine-specific rates of pertussis disease during the period of the study, among Wisconsin residents younger than 60 months of age (the Surveillance Population), and to descriptively compare the proportion of such persons vaccinated with Pentacel® vaccine who acquire pertussis disease to the proportion of such persons vaccinated with any other Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) vaccine who acquire pertussis disease. Primary Objective: To determine the rates and relative risk of pertussis disease among Surveillance Population members who have received Pentacel vaccine or another pertussis vaccine.
Interventions
- BIOLOGICAL Pentacel® (DTaP-IPV/Hib)
- BIOLOGICAL Other Pertussis Vaccines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,195 participants |
| Start Date | 2010-02-08 |
| Est. Completion | 2014-12-30 |
What the finished NCT01129362 record still lists
NCT01129362 is an observational study that tracks outcomes without assigning an intervention. Its 1,195 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Pentacel® (DTaP-IPV/Hib) is the first listed.
NCT01129362 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01129362 about?
NCT01129362 is a clinical study titled "Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines". The purpose of this cohort study is to determine vaccine-specific rates of pertussis disease during the period of the study, among Wisconsin residents younger than 60 months of age (the Surveillance Population), and to descriptively compare the proportion of such persons vaccinated with Pentacel® va...
What is the current status of trial NCT01129362?
This trial is currently completed. The enrollment target is 1,195 participants. The study started on 2010-02-08. Estimated completion is 2014-12-30.
What interventions are being tested in trial NCT01129362?
The interventions under investigation include: Pentacel® (DTaP-IPV/Hib) (BIOLOGICAL), Other Pertussis Vaccines (BIOLOGICAL).
Who is sponsoring clinical trial NCT01129362?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07177339 · 1,196 participants · Phase 3
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI